Screener
Pacific Biosciences of California PACB Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Pacific Biosciences of California in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: Pacific Biosciences of California’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 5:30 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001299130-26-000122
FAQ
- What is Pacific Biosciences of California's cash & equivalents?
- Pacific Biosciences of California (PACB) reported cash & equivalents of $62.61M in Q2 2026.
- How has Pacific Biosciences of California's cash & equivalents changed year-over-year?
- Pacific Biosciences of California's cash & equivalents increased by 10.5% year-over-year, from $56.64M to $62.61M.
- What is the long-term trend for Pacific Biosciences of California's cash & equivalents?
- Over 5 years (2020 to 2025), Pacific Biosciences of California's cash & equivalents has grown at a -5.4% compound annual growth rate (CAGR), from $85.95M to $65.26M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Pacific Biosciences of California's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude